| Amino Acid Enzymes and Metabolism | Lifetime | 13 | JP 2 | 99.72 |
| Pharmacological Receptor Mechanisms and Effects | Lifetime | 6 | JP 1 | 99.70 |
| Tryptophan and brain disorders | Lifetime | 34 | JP 1 | 99.75 |
| Neuroscience and Neuropharmacology Research | Lifetime | 142 | JP 4 | 99.75 |
| Receptor Mechanisms and Signaling | Lifetime | 136 | JP 3 | 99.51 |
| Treatment of Major Depression | Lifetime | 35 | JP 1 | 99.65 |
| Nerve injury and regeneration | Lifetime | 65 | JP 2 | 99.40 |
| Stress Responses and Cortisol | Lifetime | 135 | JP 1 | 99.36 |
| Long-Term Effects of COVID-19 | Lifetime | 177 | JP 2 | 98.27 |
| Nicotinic Acetylcholine Receptors Study | Lifetime | 119 | JP 3 | 98.62 |
| Epigenetics and DNA Methylation | Lifetime | 565 | JP 26 | 98.63 |
| Gut microbiota and health | Lifetime | 453 | JP 14 | 98.51 |
| Autism Spectrum Disorder Research | Lifetime | 294 | JP 1 | 98.40 |
| Neurotransmitter Receptor Influence on Behavior | Lifetime | 309 | JP 3 | 98.69 |
| Genomics, phytochemicals, and oxidative stress | Lifetime | 307 | JP 32 | 97.08 |
| Eicosanoids and Hypertension Pharmacology | Lifetime | 408 | JP 21 | 97.49 |
| Vagus Nerve Stimulation Research | Lifetime | 70 | JP 2 | 96.93 |
| Neuropeptides and Animal Physiology | Lifetime | 797 | JP 48 | 97.55 |
| Apelin-related biomedical research | Lifetime | 150 | JP 13 | 95.54 |
| Neurogenesis and neuroplasticity mechanisms | Lifetime | 763 | JP 47 | 96.44 |
| Cholinesterase and Neurodegenerative Diseases | Lifetime | 924 | JP 36 | 94.32 |
| Obsessive-Compulsive Spectrum Disorders | Lifetime | 728 | JP 8 | 94.40 |
| Forensic Toxicology and Drug Analysis | Lifetime | 772 | JP 33 | 91.22 |
| Nuclear Receptors and Signaling | Lifetime | 890 | JP 52 | 89.84 |
| Biochemical Acid Research Studies | Lifetime | 683 | JP 44 | 88.73 |
| Phosphodiesterase function and regulation | Lifetime | 472 | JP 29 | 88.36 |
| Psychedelics and Drug Studies | Lifetime | 541 | JP 14 | 87.41 |
| Stress Responses and Cortisol | 2021-2025 | 5 | JP 1 | 99.66 |
| Tryptophan and brain disorders | 2021-2025 | 8 | JP 1 | 99.68 |
| Vagus Nerve Stimulation Research | 2021-2025 | 1 | JP 1 | 99.48 |
| Treatment of Major Depression | 2021-2025 | 7 | JP 1 | 99.67 |
| Gut microbiota and health | 2021-2025 | 63 | JP 1 | 99.23 |
| Neurotransmitter Receptor Influence on Behavior | 2021-2025 | 47 | JP 1 | 97.33 |
| Diet and metabolism studies | 2021-2025 | 311 | JP 3 | 96.66 |
| Clostridium difficile and Clostridium perfringens research | 2021-2025 | 133 | JP 2 | 94.14 |
| Intensive Care Unit Cognitive Disorders | 2021-2025 | 715 | JP 22 | 90.27 |
| Eicosanoids and Hypertension Pharmacology | 2021-2025 | 105 | JP 3 | 86.28 |
| Pharmacological Receptor Mechanisms and Effects | 2021-2025 | 85 | JP 1 | 84.98 |
| Anesthesia and Neurotoxicity Research | 2021-2025 | 583 | JP 11 | 78.71 |
| Psychedelics and Drug Studies | 2021-2025 | 295 | JP 1 | 82.49 |
| Neuroendocrine regulation and behavior | 2021-2025 | 802 | JP 39 | 75.01 |
| Genomics, phytochemicals, and oxidative stress | 2021-2025 | 692 | JP 24 | 73.14 |
| Nuclear Receptors and Signaling | 2021-2025 | 328 | JP 13 | 68.73 |
| Biochemical Acid Research Studies | 2021-2025 | 117 | JP 6 | 71.43 |
